SEC Form 4 · accession 0001209191-16-117572
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darryl S Baker
Officer — Chief Financial Officer
Period of report
May 2, 2016
Accepted (ET)
May 4, 2016 · 7:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.44 | May 2, 2016 | A | 40,000 | A | — | May 1, 2026 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option shall vest in 48 equal monthly installments until fully vested and exercisable on May 2, 2020.